Hepatitis D screening: Difference between revisions

Jump to navigation Jump to search
Varun Kumar (talk | contribs)
No edit summary
Varun Kumar (talk | contribs)
No edit summary
Line 3: Line 3:


==Screening==
==Screening==
Drug treatment programs should screen all patients for immunity to hepatitis B. Routine screening for hepatitis D is not indicated in persons who are HBsAg positive but asymptomatic. However, the following screening and prevention procedures may be appropriate:
Drug treatment programs should screen all patients for immunity to hepatitis B. Routine screening for hepatitis D is not indicated in persons who are HBsAg positive but asymptomatic. However, the following screening and prevention procedures may be appropriate:<ref>Center for Substance Abuse Treatment. Screening for Infectious Diseases Among Substance Abusers. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1993. (Treatment Improvement Protocol (TIP) Series, No. 6.) Chapter 15 - Viral Hepatitis D.</ref>


*Patients known to be HBsAg positive who have acute or chronic hepatitis may be tested for hepatitis D. The followup care and counseling, however, of a person co-infected with hepatitis D is not different from that of a person who is HBsAg positive. Therefore, knowing if the patient is co-infected with hepatitis D is of limited clinical significance.
*Patients known to be [[HBsAg]] positive who have acute or chronic hepatitis may be tested for hepatitis D. The followup care and counseling, however, of a person co-infected with hepatitis D is not different from that of a person who is HBsAg positive. Therefore, knowing if the patient is co-infected with hepatitis D is of limited clinical significance.
*Patients with acute hepatitis B who are not yet HBsAg positive, but are immunoglobulin M (IgM) hepatitis B core antibody (anti-HBc) positive, may be tested for HDV; however, again, the presence of HDV antibody will not alter the care or counseling of such a patient.
*Patients with acute hepatitis B who are not yet HBsAg positive, but are [[immunoglobulin M]] (IgM) hepatitis B core antibody ([[anti-HBc]]) positive, may be tested for HDV; however, again, the presence of HDV antibody will not alter the care or counseling of such a patient.
*Patients who are HBsAg positive and/or HDV antibody positive should be advised not to share razors, toilet articles, or drinking and eating utensils.
*Patients who are HBsAg positive and/or HDV antibody positive should be advised not to share razors, toilet articles, or drinking and eating utensils.
*Patients who are not already immune to hepatitis B virus should be vaccinated against the virus.
*Patients who are not already immune to [[hepatitis B]] virus should be vaccinated against the virus.
*Screening is not necessary in the general population at no risk for HBV or HDV.
*Screening is not necessary in the general population at no risk for HBV or HDV.



Revision as of 14:30, 16 March 2012

Hepatitis Main Page

Hepatitis D

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hepatitis D from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis D screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis D screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis D screening

CDC on Hepatitis D screening

Hepatitis D screening in the news

Blogs on Hepatitis D screening

Directions to Hospitals Treating Hepatitis D

Risk calculators and risk factors for Hepatitis D screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]

Screening

Drug treatment programs should screen all patients for immunity to hepatitis B. Routine screening for hepatitis D is not indicated in persons who are HBsAg positive but asymptomatic. However, the following screening and prevention procedures may be appropriate:[1]

  • Patients known to be HBsAg positive who have acute or chronic hepatitis may be tested for hepatitis D. The followup care and counseling, however, of a person co-infected with hepatitis D is not different from that of a person who is HBsAg positive. Therefore, knowing if the patient is co-infected with hepatitis D is of limited clinical significance.
  • Patients with acute hepatitis B who are not yet HBsAg positive, but are immunoglobulin M (IgM) hepatitis B core antibody (anti-HBc) positive, may be tested for HDV; however, again, the presence of HDV antibody will not alter the care or counseling of such a patient.
  • Patients who are HBsAg positive and/or HDV antibody positive should be advised not to share razors, toilet articles, or drinking and eating utensils.
  • Patients who are not already immune to hepatitis B virus should be vaccinated against the virus.
  • Screening is not necessary in the general population at no risk for HBV or HDV.

References

  1. Center for Substance Abuse Treatment. Screening for Infectious Diseases Among Substance Abusers. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1993. (Treatment Improvement Protocol (TIP) Series, No. 6.) Chapter 15 - Viral Hepatitis D.

Template:WH Template:WS